Bringing hope through science

Presentation of the Q2 Interim Report 2022

Oncopeptides published its report for the second quarter 2022 on August 11, 2022, and hosted a webcast on the same day at 14:00 CET. The event was hosted by CEO, Jakob Lindberg, together with CMO Klaas Bakker and CFO Annika Muskantor. The presentation was held in English and was recorded.

Link to the webcast and more information

Webcast - CHMP issues a positive opinion recommending full approval of Oncopeptides Pepaxti in EU

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU. 

Investors, financial analysts, and media were invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event was hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor. 

More info, presentation and the webcast link

Presentation of the Q1 Report 2022

Oncopeptides published its report for the first quarter 2022 on May 4, 2022, and hosted a webcast on the same day at 11:00 CET. The event was hosted by CEO, Jakob Lindberg and members of the Oncopeptides' Leadership team. The presentation was held in English.

Link to the webcast and more information

Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US

January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto^® in the US.

Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).

The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.

More info, dial in numbers and the webcast link